Clinical Trials Logo

Oesophageal Reflux clinical trials

View clinical trials related to Oesophageal Reflux.

Filter by:
  • None
  • Page 1

NCT ID: NCT05214079 Not yet recruiting - Oesophageal Reflux Clinical Trials

Determination of the Left Paratrachéal Force Required to Occlude the Esophageal Entrance

Start date: March 1, 2022
Phase: N/A
Study type: Interventional

Determine the force required to occlude the esophagus with a left paratracheal pressure

NCT ID: NCT05060744 Recruiting - Gastric Reflux Clinical Trials

Efficacy and Speed of Action of a Product to Control Gastric Hydration and Gastroesophageal Reflux

AQUAA
Start date: September 9, 2021
Phase: N/A
Study type: Interventional

A Randomised, Placebo-Controlled Clinical Trial off the Efficacy and Rapidity of Action of a Product Containing Sodium Alginate, Calcium and Magnesium Salts, Hyaluronic Acid and Aloe Vera to Control Oesophageal-Gastric pH and Reduce Symptoms of Gastric Reflux and Hyperacidity.

NCT ID: NCT03835663 Active, not recruiting - Gastric Cancer Clinical Trials

The Bacterial Composition of the Stomach in Reflux Disease

Start date: June 4, 2018
Phase:
Study type: Observational

Gastric and oesophageal (OG) cancer associated with poor long term outcome as overall less than 25% of patients survive for more than 5 years due to late recognition of the disease. Growing evidence suggests an important role for bacteria in OG cancer and gastro esophageal reflux disease (GORD) development. About 1 in 10 people suffer from GORD and this one of the most common conditions leading to gastric and oesophageal cancer. In GORD surgical therapy is the most successful preventing cancer but around 85% of patient experience complications afterwards. Acid suppressing medications are reducing the risk of oesophageal cancer but equally increasing the risk of gastric cancer. They also shorten patients' life expectancy and often fail to provide relief. Analysis of stool samples of patients with GORD demonstrated different gut bacterial compositions to normal and rather resembled the one found in cancer. There is a clear need to improve the outcome of OG cancer. This could be achieved by identifying bacteria responsible for cancer development in gastric tissue, gastric content and saliva and potentially eliminate them hence avoid the development of cancer.